Trial Profile
A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Jun 2022
Price :
$35
*
At a glance
- Drugs Entinostat (Primary)
- Indications Breast cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Syndax Pharmaceuticals
- 01 Jun 2022 Status changed from withdrawn prior to enrolment to discontinued.
- 12 Jan 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
- 12 Jan 2009 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.